|
1.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2011. View Article : Google Scholar
|
|
2.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
3.
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Pinnix ZK, Miller LD, Wang W, D’Agostino R
Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti
SV and Torti FM: Ferroportin and iron regulation in breast cancer
progression and prognosis. Sci Transl Med. 2:43ra562010. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Torti SV and Torti FM: Ironing out cancer.
Cancer Res. 71:1511–1514. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Miller LD, Cofman LG, Chou JW, Black MA,
Bergh J, D’Agostino R Jr, Torti SV and Torti FM: An iron gene
signature predicts outcome in breast cancer. Cancer Res.
71:6728–6737. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Kwok JC and Richardson DR: The iron
metabolism of neoplastic cells: alterations that facilitate
proliferation? Crit Rev Oncol Hematol. 42:65–78. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Yu Y, Gutierrez E, Kovacevic Z, Saletta F,
Obeidy P, Rahmanto YS and Richardson DR: Iron chelators for the
treatment of cancer. Curr Med Chem. 19:2689–2702. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Hoke EM, Maylock CA and Shacter E:
Desferal inhibits tumor growth and does not interfere with
tumoricidal activity of doxorubicin. Free Radic Biol Med.
39:403–411. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Rao VA, Klein SR, Agama KK, Toyoda E,
Adaci N, Pommier Y and Shacter EB: The iron chelator Dp44mT causes
DNA damage and selective inhibition of topoisomerase II alpha in
breast cancer cells. Cancer Res. 69:948–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Whitnall M, Howard J, Ponka P and
Richardson DR: A class of iron chelators with a wide spectrum of
potent antitumor activity that overcomes resistance to
chemotherapeutics. Proc Natl Acad Sci USA. 103:14901–14906. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Chekhun VF, Lukyanova NYu, Kovalchuk O,
Tryndyak VP and Pogribny IP: Epigenetic profiling of
multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals
novel hyper- and hypomethylated targets. Mol Cancer Ther.
6:1089–1098. 2007. View Article : Google Scholar
|
|
13.
|
Kars MD, Iseri OD, Gündüz U, Ural AU,
Arpaci F and Molnár J: Development of rational in vitro models for
drug resistance in breast cancer and modulation of MDR by selected
compounds. Anticancer Res. 26:4559–4568. 2006.PubMed/NCBI
|
|
14.
|
Pate KT, Randel NA, Fraser B, Clement MH
and Srinivasan C: Measuring ‘free’ iron levels in Caenorhabditis
elegans using low-temperature Fe(III) electron paramagnetic
resonance spectroscopy. Anal Biochem. 358:199–207. 2006.
|
|
15.
|
McClelland RA, Wilson D and Leake R: A
multicentre study into the reliability of steroid receptor
immunocytochemical assay quantification. Eur J Cancer. 27:711–715.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Skehan P, Storeng R, Scudiero D, Monks A,
McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR:
New colorimetric cytotoxicity assay for anticancer-drug screening.
J Natl Cancer Inst. 82:1107–1112. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Ni J and Hollander D: Application of the
MTT-assay to functional studies of mouse intestinal intraepithelial
lymphocytes. J Clin Lab Anal. 10:42–52. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Shpyleva SI, Tryndyak VP, Kovalchuk O,
Starlard-Davenport A, Chekhun VF, Beland FA and Pogribny IP: Role
of ferritin alterations in human breast cancer cells. Breast Cancer
Res Treat. 126:63–71. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Arosio P, Ingrassia and Cavadini P:
Ferritins: a family of molecules for iron storage, antioxidation
and more. Biochim Biophys Acta. 1790:589–599. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Dorr RT: Bleomycin pharmacology: mechanism
of action and resistance and clinical pharmacokinetics. Semin
Oncol. 19(Suppl 5): 3–8. 1992.PubMed/NCBI
|
|
21.
|
Wu Z, Wang C, Xiang R, Liu X, Ye S, Yang
X, Zhang G, Xu X, Zhu T and Wu Q: Loss of miR133a expression is
associated with poor survival of breast cancer and restoration of
miR-133a expression inhibited breast cancer growth and invasion.
BMC Cancer. 12:512012. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Kovalchuk O, Filkowski J, Meservy J,
Ilnytskyy Y, Tryndyak VP, Chekhun VF and Pogribny IP: Involvement
of microRNA-451 in resistance of the MCF-7 breast cancer cells to
chemotherapeutic drug doxorubicin. Mol Cancer Ther. 7:2152–2159.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Pogribny IP, Filkowski JN, Tryndyak VP,
Golubov A, Shpyleva SI and Kovalchuk O: Alterations of microRNAs
and their targets are associated with acquired resistance of MCF-7
breast cancer cells to cisplatin. Int J Cancer. 127:1785–1794.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Kanojia D, Zhou W, Zhang J, Jie C, Lo PK,
Wang Q and Chen H: Proteomic profiling of cancer stem cells from
primary tumors of HER2/Neu transgenic mice. Proteomics.
12:3407–3415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Eswaran J, Cyanam D, Mudravi P, Reddy SD,
Pakala SB, Nair SS, Florea L, Fuqua SA, Godbole S and Kumar R:
Transcriptomic landscape of breast cancers through mRNA sequencing.
Sci Rep. 2:2642012. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Descotes F, Jézéquel P, Spyratos F,
Campion L, Grenot C, Lerebours F, Campone M, Guérin-Charbonnel C,
Lanoë D, Adams M, andré J, Carlioz A, Martin PM, Chassevent A,
Jourdan ML, Guette C, Zanella-Cleon I and Ricolleau G:
Identification of potential prognostic biomarkers for node-negative
breast tumours by proteomic analysis: a multicentric 2004 national
PHRC study. Int J Oncol. 41:92–104. 2012.PubMed/NCBI
|
|
27.
|
Dong X, Yang M, Sun H, Lü J, Zheng Z, Li Z
and Zhong L: Combined measurement of CA 15-3 with novel
autoantibodies improves diagnostic accuracy for breast cancer. Onco
Targets Ther. 6:273–279. 2013.PubMed/NCBI
|
|
28.
|
Xu X, Persson HL and Richardson DR:
Molecular pharmacology of the interaction of anthracyclines with
iron. Mol Pharmacol. 68:261–271. 2005.PubMed/NCBI
|
|
29.
|
Xu X, Sutak R and Richardson DR: Iron
chelation by clinically relevant anthracyclines: alteration in
expression of iron-regulated genes and atypical changes in
intracellular iron distribution and trafficking. Mol Pharmacol.
73:833–844. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Canzoneri JC and Oyelere AK: Interaction
of anthracyclines with iron responsive elements mRNAs. Nucleic
Acids Res. 36:6825–6834. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Thompson KJ, Fried MG, Ye Z, Boyer P and
Connor JR: Regulation, mechanisms and proposed function of ferritin
trans-location to cell nuclei. J Cell Sci. 114:2165–2177.
2002.PubMed/NCBI
|
|
32.
|
Alkhateeb AA and Connor JR: Nuclear
ferritin: a new role for ferritin in cell biology. Biochim Biophys
Acta. 1800:793–797. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Yang DC, Jiang X, Elliot RL and Head JF:
Antisense ferritin oligonucleotides inhibit growth and induce
apoptosis in human breast carcinoma cells. Anticancer Res.
22:1513–1524. 2002.
|
|
34.
|
Liu X, Madhankumar AB, Slagle-Webb B,
Sheehan JM, Surguladze N and Connor JR: Heavy chain ferritin siRNA
delivered by cationic liposomes increases sensitivity of cancer
cells to chemotherapeutic agents. Cancer Res. 71:2240–2249. 2011.
View Article : Google Scholar
|
